comparemela.com

Latest Breaking News On - Jiangsu recbio technology co - Page 2 : comparemela.com

Superior Neutralizing Antibody Titer Levels Against Omicron BF 7 And BA 2 75 Of The Company s Two-Component Recombinant COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine

/PRNewswire/ Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results.

Jiangsu Recbio Technology Co , Ltd Increases Production For The First Phase Of Manufacturing Facility With A Maximum Annual Output Of 20 Million Doses Of Recombinant HPV 9-Valent Vaccine

/PRNewswire/ (the "Company", together with its subsidiaries, the "Group") on voluntary basis. The board of directors of the Company (the "Board") is pleased.

vimarsana © 2020. All Rights Reserved.